{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:46:14Z","timestamp":1788281174147,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Novel therapeutic agents are currently being investigated for neuroendocrine tumour treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>We report here on the case of a patient presenting with hypersensitivity pneumonitis while being treated with everolimus, a mammalian target of rapamycin (mTOR) inhibitor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Side effects of everolimus should be familiar to clinicians, including nonspecialists, and be monitored carefully to allow for prompt management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-0500-6-471","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T01:25:27Z","timestamp":1384824327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report"],"prefix":"10.1186","volume":"6","author":[{"given":"Camille","family":"Sibertin-Blanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Norguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Duluc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,18]]},"reference":[{"issue":"2","key":"2489_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","volume":"28","author":"E Missiaglia","year":"2010","unstructured":"Missiaglia E, Dalai I, Barbi S: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010, 28 (2): 245-255. 10.1200\/JCO.2008.21.5988.","journal-title":"J Clin Oncol"},{"key":"2489_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Disc. 2006, 5: 671-688. 10.1038\/nrd2062.","journal-title":"Nat Rev Drug Disc"},{"key":"2489_CR3","volume-title":"Eur J Cancer","author":"M Pavel","year":"2010","unstructured":"Pavel M, Hainsworth JD, Baudin E: A randomized double blind, placebo-controlled multicenter phase III trial of everolimus plus octreotide LAR vs placebo plus Octreotide LAR in patients with advanced neuroendocrine tumors (Radiant-2). Eur J Cancer. 2010, LBA8"},{"issue":"6","key":"2489_CR4","first-page":"514","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T: RAD001 In advanced neuroendocrine tumors, third trial (RADIANT-3) study group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011, 364 (6): 514-523.","journal-title":"Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med"},{"issue":"3","key":"2489_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","volume":"182","author":"DA White","year":"2010","unstructured":"White DA, Camus P, Endo M: Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010, 182 (3): 396-403. 10.1164\/rccm.200911-1720OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"2489_CR6","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1097\/JTO.0b013e3181ba20b1","volume":"4","author":"DA White","year":"2009","unstructured":"White DA, Schwartz LH, Dimitrijevic S: Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol. 2009, 4 (11): 1357-1363. 10.1097\/JTO.0b013e3181ba20b1.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"2489_CR7","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1016\/j.transproceed.2010.07.066","volume":"42","author":"P Errasti","year":"2010","unstructured":"Errasti P, Izquierdo D, Mart\u00edn P: Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc. 2010, 42 (8): 3053-3054. 10.1016\/j.transproceed.2010.07.066.","journal-title":"Transplant Proc"},{"issue":"6","key":"2489_CR8","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.transproceed.2009.06.003","volume":"41","author":"A Rodr\u00edguez-Moreno","year":"2009","unstructured":"Rodr\u00edguez-Moreno A, Ridao N, Garc\u00eda-Ledesma P: Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc. 2009, 41 (6): 2163-2165. 10.1016\/j.transproceed.2009.06.003.","journal-title":"Transplant Proc"},{"issue":"1","key":"2489_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.healun.2008.10.003","volume":"28","author":"J Otton","year":"2009","unstructured":"Otton J, Hayward CS, Keogh AM: Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant. 2009, 28 (1): 104-106. 10.1016\/j.healun.2008.10.003.","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"2489_CR10","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1016\/j.transproceed.2010.07.083","volume":"42","author":"AI S\u00e1nchez-Fructuoso","year":"2010","unstructured":"S\u00e1nchez-Fructuoso AI, Ruiz JC, P\u00e9rez-Flores I: Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transplant Proc. 2010, 42 (8): 3050-3052. 10.1016\/j.transproceed.2010.07.083.","journal-title":"Transplant Proc"},{"issue":"10","key":"2489_CR11","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1093\/ndt\/gfn401","volume":"23","author":"S Alexandru","year":"2008","unstructured":"Alexandru S, Ortiz A, Baldovi S: Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant. 2008, 23 (10): 3353-3355. 10.1093\/ndt\/gfn401.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2489_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.healun.2008.03.016","volume":"27","author":"V Exp\u00f3sito","year":"2008","unstructured":"Exp\u00f3sito V, de Prada JA, G\u00f3mez-Rom\u00e1n JJ: Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant. 2008, 27 (7): 797-800. 10.1016\/j.healun.2008.03.016.","journal-title":"J Heart Lung Transplant"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-6-471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:15:01Z","timestamp":1630548901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-6-471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,18]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2489"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-6-471","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,18]]},"assertion":[{"value":"8 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"471"}}